Fujiki, Shinya
Iijima, Kenichi
Nakagawa, Yoshihisa
Takahashi, Kazuyoshi
Okabe, Masaaki
Kusano, Kengo
Owada, Shingen
Kondo, Yusuke
Tsujita, Kenichi
Shimizu, Wataru
Tomita, Hirofumi
Watanabe, Masaya
Shoda, Morio
Watanabe, Masafumi
Tokano, Takashi
Murohara, Toyoaki
Kaneshiro, Takashi
Kato, Takeshi
Hayashi, Hidemori
Maemura, Koji
Niwano, Shinichi
Umemoto, Tomio
Yoshida, Hisako
Ota, Keiko
Tanaka, Takahiro
Kitamura, Nobutaka
Node, Koichi
Minamino, Tohru
,
Funding for this research was provided by:
Nippon Boehringer Ingelheim Co. Ltd. and Eli Lilly and Company
AMED-CREST (JP20gm1110012)
Moonshot Research and Development Program (21zf0127003s0201)
Article History
Received: 25 March 2024
Accepted: 16 June 2024
First Online: 28 June 2024
Declarations
:
: The trial was approved by the Certified Review Board of the Niigata University Graduate School of Medicine and was performed in compliance with the Declaration of Helsinki and the Clinical Trials Act. All enrolled patients provided written informed consent prior to eligibility screening.
: All authors have read and approved the submission of the manuscript.
: S.F. received funding support of present manuscript from Nippon Boehringer Ingelheim Co. Ltd, Eli Lilly and Company. Y.N. received grant and speaking honoraria from Nippon Boehringer Ingelheim. K.K. received honoraria for lectures from Medtronic, Boehringer-Ingelheim. Y.K. received speaking honoraria from Biotronik Japan, Boston Scientific Japan, Daiichi-Sankyo, Bayer Yakuhin, Abbott Medical Japan, Japan Lifeline, and received research grant from Daiichi-Sankyo. K.Tsujita received scholarship fund from Boehringer Ingelheim Japan. W.S. received grant from Nippon Boehringer Ingelheim, Daiichi Sankyo Company, Ltd., and received speaking honoraria from Nippon Boehringer Ingelheim, Daiichi Sankyo Company, Ltd.,Bristol-Meyers Squibb, Bayer Yakuhin, Pfizer, Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Johnson and Johnson KK, Medtronic Japan. H.T. received grant from Medtronic Japan Co., Ltd., Fukuda Denshi Kita-tohoku Hanbai Co., Ltd., BIOTRONIK Japan Co., Ltd., Japan Lifeline Co., and Boston Scientific Japan Co., Ltd., and received speaking honoraria from Boehringer Ingelheim. Masaya Watanabe received grant from Japan Society for the Promotion of Science and CASIO SCIENCE PROMOTION FOUNDATION. Masafumi Watanabe received grant from DAIICHI SANKYO COMPANY, LIMITED, CHUGAI PHARMACEUTICAL CO., LTD, Boston Scientific Corporation, Abbott Vascular Japan Co., Ltd, Cardinal Health, KANEKA MEDIX CORP, BIOTRONIK Japan, Inc, FUKUDA DENSHI, MEDTRONIC JAPAN CO., LTD, and received speaking honoraria from Otsuka Pharmaceutical Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Nippon Boehringer Ingelheim Co., Ltd. T.Murohara received from Japan Boehringer Inc., Ono Pharmaceutical Inc., Daiichi- Sankyo Inc., AstraZeneca Inc. T.Kato received honoraria for lectures from Boehringer-Ingelheim, AstraZeneca, Ono Pharmaceutical, Medtronic, BIOTRONIK, Boston Scientific, Abbott. K.M. received grant from Daiichi-Sankyo, and received honoraria for lectures from Daiichi-Sankyo, Novartis, Takeda, Pfizer, Nippon Boehlinger ingelheim. K.N. received speaking honoraria from Astellas, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, Novo Nordisk Pharma, Novartis Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, MSD. T.Minamino received funding support for the present study, provision of study drugs and remuneration for lectures from Nippon Boehringer Ingelheim and Eli Lilly. K.I., K.Takahashi, M.O., S.O., M.S., T.Tokano, T.Kaneshiro, H.H., S.N., T.U., H.Y., K.O., T.Tanaka, N.K. declare no competing interests.